Roche Reports Updated Data of Alecensa in P-III ALEX Study for Patients with ALK-Positive Non-Small Cell Lung Cancer

 Roche Reports Updated Data of Alecensa in P-III ALEX Study for Patients with ALK-Positive Non-Small Cell Lung Cancer

Roche Reports Updated Data of Alecensa in P-III ALEX Study for Patients with ALK-Positive Non-Small Cell Lung Cancer

Shots:

  • The P-III ALEX study involves assessing of Alecensa vs crizotinib in 303 treatment-naïve patients in a ratio (1:1) with ALK+ NSCLC whose tumors were characterized as ALK+ by the VENTANA ALK (D5F3) CDx Assay
  • Updated results: OS @5yrs. (62.5% vs 45.5%); reduction in the risk of death in patients with/ without CNS metastases (42%/ 24%) respectively, updated data confirms Alecensa’s safety & tolerability. The updated data follows mPFS data, presented at ESMO 2019 which demonstrated 57% reduction in risk of disease worsening or death
  • Alecensa (RG7853/AF-802/RO5424802/CH5424802) is a highly selective, CNS active, oral therapy, being developed for people with ALK+ NSCLC and has received approval in 88+ countries as 1L treatment for ALK+ m-NSCLC including in the US, EU, Japan and China

Click here ­to­ read full press release/ article | Ref: Roche | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post